1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow EspeRare Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia ER004 - X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | Phase 2 | Recruiting | EspeRare Foundation | 20 | 2022-04-26 | 2025-04-30 |
| Rimeporide in Patients With Duchenne Muscular Dystrophy Rimeporide - Muscular Dystrophy, Duchenne | Phase 1 | Completed | EspeRare Foundation | 20 | 2016-03-01 | 2019-07-18 |
Ectodermal Dysplasia 1, Anhidrotic (1) · Muscular Dystrophy, Duchenne (1)
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine (1)
France (2) · Italy (2) · Spain (2) · United Kingdom (2) · Germany (1) · United States (1)
2015 (1)